The aggregation of α-synuclein in neurons is characteristic of Parkinson disease. Koprich, Kalia and Brotchie provide a critical overview of preclinical, mammalian models of α-synucleinopathy and their merits and limitations in drug development for Parkinson disease, and suggest a combination of different models for optimal proof-of-principle investigation of novel therapeutics.
- James B. Koprich
- Lorraine V. Kalia
- Jonathan M. Brotchie
